Daniel C Adelman

Author PubWeight™ 5.92^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials.	Dig Dis Sci	2011	1.21
2	A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors.	Invest New Drugs	2007	1.11
3	Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer.	J Thorac Oncol	2011	1.04
4	Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results.	Circulation	2003	0.99
5	Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.	Clin Cancer Res	2010	0.91
6	Photodynamic therapy: applications in atherosclerotic vascular disease with motexafin lutetium.	Catheter Cardiovasc Interv	2002	0.76
7	Pharmacological approaches.	Clin Allergy Immunol	2002	0.75